Renaissance Technologies
CTNM

Renaissance Technologies’s Contineum Therapeutics CTNM Stock Holding History

Renaissance Technologies’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
67,300
-2,100
-3% -$27.5K ﹤0.01% 2262
2026
Q1 		$906K Buy
69,400
+12,300
+22% +$165K ﹤0.01% 2322
2025
Q4 		$653K Buy
57,100
+15,900
+39% +$181K ﹤0.01% 2470
2025
Q3 		$484K Buy
41,200
+26,796
+186% +$216K ﹤0.01% 2809
2025
Q2 		$57.2K Buy
+14,404
New +$62.6K ﹤0.01% 3376

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies's CTNM Position: Q2 2026 in Review

Renaissance Technologies reduced its Contineum Therapeutics (CTNM) stake by 3% in Q2 2026, selling an estimated $27.5K and leaving 67,300 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2262.

Renaissance Technologies first reported a position in CTNM in Q2 2025 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Renaissance Technologies held 67,300 shares of Contineum Therapeutics worth $1.1M as of Q2 2026.
  • Renaissance Technologies sold 2,100 Contineum Therapeutics shares in Q2 2026, an estimated $27.5K.
  • Contineum Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2262 holding.
  • Renaissance Technologies first reported a position in Contineum Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.